| Keywords: |
treatment response; review; nonhuman; neoplasm; neoplasms; t lymphocyte; t-lymphocytes; cancer immunotherapy; multiple myeloma; food and drug administration; transplantation; oncology; acute lymphoblastic leukemia; immunology; hematologic malignancy; recombinant fusion proteins; genetic engineering; receptors, antigen, t-cell; glioblastoma; remission; remission induction; pancreas adenocarcinoma; chimeric antigen receptor; adoptive transfer; chronic lymphatic leukemia; follicular lymphoma; cd19 antigen; lymphocyte antigen receptor; antigens, cd19; fusion protein; synthetic biology; procedures; diffuse large b cell lymphoma; cell engineering; humans; human; priority journal; malignant neoplasm; chimeric antigen receptor t-cell immunotherapy; immunooncology
|
